First oral #SERD approved for HR+ metastatic #bcsm w/ ESR1 mutation- welcome #elacestrant.

Much more work being done with this class of compounds including: 1) earlier settings, 2) combinations, 3) additional novel oral SERDs coming, 4) benefit in all comers.

@OncoAlert@twitter.com